Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APLS Apellis Pharmaceuticals Inc.

交易中 04-10 11:38:32 EDT

40.69

+0.04

+0.10%

最高40.73	最低40.65	成交量254.38万
今开40.68	昨收40.65	日振幅0.20%
总市值52.01亿	流通市值31.79亿	总股本1.28亿
成交额1.03亿	换手率3.26%	流通股本7,812万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":40.69,"timestamp":1775835503406,"preClose":40.65,"halted":0,"volume":2543760,"delay":0,"changeRate":0.00098400984009838,"floatShares":78119932,"shares":127829909,"eps":0.172407,"marketStatus":"交易中","change":0.04,"latestTime":"04-10 11:38:32 EDT","open":40.68,"high":40.7301,"low":40.65,"amount":103494033.01079999,"amplitude":0.00197,"askPrice":40.69,"askSize":2594,"bidPrice":40.68,"bidSize":4508,"shortable":3,"etf":0,"ttmEps":0.172407,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775851200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":40.65,"preHourTrading":{"tag":"盘前","latestPrice":40.6,"preClose":40.65,"latestTime":"08:13 EDT","volume":8,"amount":323.97728,"timestamp":1775823236281,"change":-0.05,"changeRate":-0.00123,"amplitude":0.003444},"postHourTrading":{"tag":"盘后","latestPrice":40.65,"preClose":40.65,"latestTime":"19:23 EDT","volume":557719,"amount":22671306.1108,"timestamp":1775776999983,"change":0,"changeRate":0,"amplitude":0.000984},"volumeRatio":1.188144,"impliedVol":0.0957,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/APLS/tweets","defaultTab":"tweets","newsList":[{"id":"1120097605","title":"Baird下调Apellis评级至中性 目标价砍至41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120097605","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120097605?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:19","pubTimestamp":1775013553,"startTime":"0","endTime":"0","summary":"投资机构Baird宣布，将生物制药公司Apellis Pharmaceuticals Inc.的股票评级从“跑赢大盘”下调至“中性”。与此同时，该机构将其目标股价从52美元大幅调降至41美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","APLS","BK4585","BK4139","LU1093756325.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149102155","title":"渤健公司同意以56亿美元收购Apellis Pharmaceuticals，股价跌至1月以来最低点，日内跌幅达7.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149102155","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149102155?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:33","pubTimestamp":1774963995,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）股价遭遇重挫，在宣布将以56亿美元收购Apellis Pharmaceuticals Inc.后，盘中跌幅一度扩大至7.7%，创下自今年1月以来的最低水平。此次收购协议引发市场对渤健公司财务负担和整合前景的担忧，投资者纷纷抛售股票，导致其股价承压下行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B19Z9P08.USD","LU0109394709.USD","BK4139","LU0320765992.SGD","BK4505","LU0234570918.USD","BIIB","APLS","IE00B894F039.SGD","BK4588","LU0889565916.HKD","BK4533","LU1093756168.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858686","title":"Apellis(APLS)盘前涨超142% Biogen(BIIB)将以56亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623858686?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:31","pubTimestamp":1774956713,"startTime":"0","endTime":"0","summary":"金吾财讯| Apellis Pharmaceuticals(APLS)盘前涨超142%，每股报41.05美元。消息面上，Biogen Inc.已同意以56亿美元收购Apellis Pharmaceuticals Inc.，扩大其在免疫学和罕见病领域的治疗能力，这是该公司有史以来规模最大的收购之一。该公司将以每股41美元的价格收购Apellis，是后者周一收盘价的两倍多。通过这笔交易，Biogen将获得两种已获批准的药物。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298590","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4505","APLS","IE00B894F039.SGD","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4533","BIIB","BK4139","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","LU0889565916.HKD","LU1093756325.SGD","BLLB","BK4588","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129135901","title":"渤健公司收购Apellis制药，强化免疫学与罕见病产品组合，提升增长前景并加速肾病领域扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1129135901","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129135901?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:59","pubTimestamp":1774954764,"startTime":"0","endTime":"0","summary":"渤健公司宣布将收购Apellis制药公司，此举将显著增强其在免疫学和罕见病领域的增长型产品组合。通过这项战略收购，渤健公司不仅进一步巩固了其增长前景，还将加速向肾病治疗领域的业务扩张步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"586db16896b94a4fd80f4a5440e9e3f1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4588","BK4585","IE00B894F039.SGD","LU0109394709.USD","LU0320765992.SGD","LU1093756325.SGD","BK4533","BK4139","IE00B19Z9P08.USD","BIIB","LU0889565916.HKD","BK4505","BK4532","APLS","LU0234570918.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166661258","title":"Biogen将以每股41美元现金加CVR（或有价值权）收购Apellis制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1166661258","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166661258?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:55","pubTimestamp":1774954525,"startTime":"0","endTime":"0","summary":"3月31日，Apellis制药盘前飙升逾140%！Biogen将以每股41美元现金加CVR（或有价值权）收购该公司。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2495f52240e7e9378faffff6c56a404","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Biogen将以每股41美元现金加CVR（或有价值权）收购Apellis制药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618853906","title":"还没进临床，就融了10亿：华人创立眼科biotech为何屡获巨头押注？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618853906","media":"药融圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618853906?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:34","pubTimestamp":1773279273,"startTime":"0","endTime":"0","summary":"CTX203旨在稳定一种名为ABCA1的蛋白质的表达水平，这种蛋白质与视网膜细胞中的脂质运输过程密切相关。合作初期将聚焦于AMD，并有望拓展至其他眼部疾病。根据协议条款，Character Bio已获得一笔首付款及年度研究资金，并有资格获得与后续开发及销售相关的里程碑付款，以及未来产品销售额的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312102852a462a024&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNY","BHC","BK4529","BK4534","BK4612","BK4585","LU0056508442.USD","LU1303367103.USD","PFE","LU1861559042.SGD","LU1242518931.SGD","AMUU","IE0004445239.USD","IE0009356076.USD","AMDL","LU0274383776.USD","LU0889565833.HKD","LU2250418816.HKD","BK4512","BK4573","LU1242518857.USD","LU0823434740.USD","LU2458330243.SGD","AMDY","BK4575","LU0082616367.USD","LU1064131342.USD","IE00B5949003.HKD","LU0109392836.USD","LU1989764664.SGD","IE00BMPRXR70.SGD","BK4605","BK4543","LU1880398471.USD","AMDU","LU1951200564.SGD","LU1923623000.USD","LU2355687059.USD","LU1852331112.SGD","BK4141","LU2931357623.SGD","RHHBY","LU2264538146.SGD","LU0642271901.SGD","BK4588","LU1988902786.USD","AMDG","LU1880398554.USD","LU2098885051.SGD","LU0823421416.USD","AMDD","BK4554","BK4614","LU0081259029.USD","LU0979878070.USD","LU2054465674.USD","AMDW","AMD","BK4566","LU2458330169.SGD","AMYY","LU1316542783.SGD","BK4532","LU1951198990.SGD","LU0823434583.USD","APLS","DAMD","IE00BMPRXN33.USD","LU2089985449.USD","LU2360106780.USD","LU0390134368.USD","LU1861558580.USD","LU1803068979.SGD","LU0719512351.SGD","LU0127658192.USD","LU0823421333.USD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1131834580","title":"财报前瞻｜Apellis Pharmaceuticals Inc.本季度营收预计增0.44%，机构观点中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1131834580","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131834580?lang=zh_cn&edition=full","pubTime":"2026-02-17 11:55","pubTimestamp":1771300528,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc.将于2026年02月24日发布新一季财报，市场聚焦营收增速放缓与利润率承压的权衡。市场一致预期本季度Apellis Pharmaceuticals Inc.营收为1.99亿美元，同比增加0.44%，每股收益预计为-0.38美元，同比改善0.97%，息税前利润预计为-0.42亿美元，同比下降13.27%；当前无一致口径的毛利率与净利润预测，故不做展示。Apellis Pharmaceuticals Inc.上季度营收为4.59亿美元，同比增长132.98%；毛利率为79.78%；归属于母公司股东的净利润为2.16亿美元，对应净利率47.04%；调整后每股收益为1.67美元，同比增长463.04%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Apellis Pharmaceuticals Inc.本季度营收预计增0.44%，机构观点中性","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1129979339","title":"标普道琼斯指数：TTM科技、Dutch Bros、先进能源工业和美国医疗保健REIT将纳入标普400中型股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1129979339","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129979339?lang=zh_cn&edition=full","pubTime":"2026-01-28 07:06","pubTimestamp":1769555210,"startTime":"0","endTime":"0","summary":"根据标普道琼斯指数公司最新公告，四家企业——TTM科技、Dutch Bros、先进能源工业和美国医疗保健房地产投资信托基金，已确定将被纳入标普400中型股指数。\n此次调整反映了指数成分股的定期更新，旨在确保指数能持续代表美国中型股市场的表现。新成员的加入通常意味着这些公司满足了特定的市值和流动性要求，市场关注度有望随之提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","BK4585","BK4505","BK4588","BK4139","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102625504","title":"Apellis制药获美银证券上调至买入评级 盘前股价应声上涨3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102625504","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102625504?lang=zh_cn&edition=full","pubTime":"2026-01-21 19:49","pubTimestamp":1768996165,"startTime":"0","endTime":"0","summary":"在美银证券全球研究部门将其评级从“中性”上调至“买入”后，Apellis Pharmaceuticals Inc. (APLS) 股价于盘前交易时段上涨3.7%。此次评级上调反映了市场对该制药公司前景的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4139","BK4588","BK4585","APLS","BK4505","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136676968","title":"Apellis在第44届摩根大通医疗健康大会上强调商业执行与战略重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1136676968","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136676968?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:03","pubTimestamp":1768219438,"startTime":"0","endTime":"0","summary":"在近日举行的第44届摩根大通医疗健康大会上，Apellis Pharmaceuticals Inc. 重点阐述了其商业执行进展与核心战略方向。公司管理层详细介绍了在关键市场的推广策略与产品管线的最新动态，强调了其对实现长期增长目标的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","APLS","BK4588","LU1093756168.USD","LU1093756325.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593362432","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘快速拉升5.05%报25.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593362432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593362432?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:26","pubTimestamp":1766420813,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日00时26分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.05%。截至发稿，该股报25.90美元/股，成交量98.0499万股，换手率0.77%，振幅6.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物， 通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223002653953b84f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223002653953b84f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4505","APLS","BK4588","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164590450","title":"Apellis Pharmaceuticals：Syfovre五年来的安全性概况与之前报告的数据一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164590450","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164590450?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:09","pubTimestamp":1762949354,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals：Syfovre五年来的安全性概况与之前报告的数据一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS","LU1093756325.SGD","BK4505","LU1093756168.USD","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164914277","title":"Apellis公布5年Gale数据，显示Syfovre®（Pegcetacoplan注射液）将地理性萎缩进展延迟约1.5年","url":"https://stock-news.laohu8.com/highlight/detail?id=1164914277","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164914277?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:06","pubTimestamp":1762949194,"startTime":"0","endTime":"0","summary":"Apellis公布5年Gale数据，显示Syfovre®（Pegcetacoplan注射液）将地理性萎缩进展延迟约1.5年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","LU1093756325.SGD","BK4585","APLS","BK4139","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179108448","title":"Apellis Pharmaceuticals 第三季度基本每股收益为 1.71 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179108448","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179108448?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:25","pubTimestamp":1761823557,"startTime":"0","endTime":"0","summary":"10月30日 - Apellis Pharmaceuticals 第三季度净收入为 2.15715 亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1093756168.USD","APLS","BK4588","LU1093756325.SGD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518428998","title":"Apellis Pharmaceuticals, Inc.2024财年实现净利润-1.98亿美元，同比增加62.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518428998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518428998?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449653,"startTime":"0","endTime":"0","summary":"3月9日，Apellis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-1.98亿美元，同比增加62.57%；其中营业收入为7.81亿美元，同比增加96.73%，每股基本收益为-1.60美元。从资产负债表来看，Apellis Pharmaceuticals, Inc.总负债6.57亿美元，其中短期债务6.75百万美元，资产负债比为1.35，流动比率为4.25。机构评级：截至2025年3月9日，当前有20家机构对Apellis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为43.60美元，其中最低目标价为25.00美元，最高目标价为75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130319973","title":"异动解读 | 生物技术公司Apellis Pharmaceuticals股价盘中大涨5.26%,业绩数据和机构看好预期或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1130319973","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130319973?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:46","pubTimestamp":1741117592,"startTime":"0","endTime":"0","summary":"APLS在2025年3月4日周二盘中出现大涨5.26%的行情,引发了市场广泛关注。\n\n分析人士认为,可能是该公司最新财报数据令投资者对其长期前景看好所致。财报显示,公司去年实现营收7.81亿美元,虽然净利润略为负数,但在生物技术行业中表现尚可。同时大部分机构给予该股买入或持有评级,认为其在新药研发领域具备较强实力。\n\nAPLS是一家商业化阶段的生物制药公司,专注于免疫系统中补体反应通路相关疾病的新药研发。行业分析人士认为,公司在补体领域的技术储备较为丰富,若能顺利推出有突破性的产品,长期前景值得期待。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 生物技术公司Apellis Pharmaceuticals股价盘中大涨5.26%,业绩数据和机构看好预期或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517798801","title":"Apellis Pharmaceuticals, Inc.盘中异动 大幅拉升5.03%报25.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517798801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517798801?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:36","pubTimestamp":1741117017,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时36分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033657a25f58e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305033657a25f58e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4139","BK4585","LU1093756168.USD","BK4505","BK4588","APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192955750","title":"异动解读 | 投行下调目标价致使Apellis Pharmaceuticals盘中股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192955750","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192955750?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:16","pubTimestamp":1741025814,"startTime":"0","endTime":"0","summary":"生物科技公司Apellis Pharmaceuticals(APLS)今日盘中股价大幅下挫,引发市场密切关注。\n\n投行高盛(GS)下调了该公司的股票目标价,成为该股大跌的主要推手。高盛将Apellis Pharmaceuticals的目标价由之前的36美元下调至32美元,但维持中性投资评级不变。\n\n作为分析师报告下调目标价的主要原因尚未透露,但投资者担心公司增长前景或盈利能力未达预期,导致股票遭到抛售。Apellis Pharmaceuticals盘中一度下跌逾5%,市值蒸发数亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 投行下调目标价致使Apellis Pharmaceuticals盘中股价大跌5.05%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516365458","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘急速下挫5.09%报23.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516365458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516365458?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:13","pubTimestamp":1741025601,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时13分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.09%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021322abe6743e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021322abe6743e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4588","LU1093756168.USD","APLS","BK4505","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516632237","title":"高盛：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由36.00美元调整至32.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632237","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632237?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:54","pubTimestamp":1741013661,"startTime":"0","endTime":"0","summary":"高盛：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由36.00美元调整至32.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03225448494325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":1.0698},{"period":"3month","weight":0.489},{"period":"6month","weight":0.6182},{"period":"1year","weight":1.0729},{"period":"ytd","weight":0.6182}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过在补体级联中的中心蛋白C3水平上抑制补体系统（作为免疫系统的一个组成部分）来治疗具有高度未满足需求的疾病。2023年2月，美国食品药品监督管理局（FDA）批准了SYFOVRE，这是首个获批治疗继发于年龄相关性黄斑变性（GA）的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.555556,"avgChangeRate":0.020983},{"month":3,"riseRate":0.555556,"avgChangeRate":0.121941},{"month":4,"riseRate":0.666667,"avgChangeRate":0.036509},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}